Genoptix | GenomeWeb


The test, which relies on multiplex IHC and imaging to calculate a PD-1/PD-L1 interaction score, predicted response in melanoma patients better than PD-L1 testing alone.

NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics today said that it has named Genoptix BioPharma Services as its first partner under its CLIA Certified RNAscope Service Provider program.

Trovagene announced last month that it has granted Novartis' diagnostics laboratory, Genoptix, a worldwide, non-exclusive license to incorporate the nucleophosmin protein marker into research and clinical testing services for acute myelogenous leukemia.

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted to Genoptix a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia.

The acquisition, announced Jan. 24, "complements the Novartis internal capabilities aimed at improving health outcomes by advancing individualized treatment programs," Novartis said in a statement.

Novartis will add the personalized diagnostics lab services to its molecular diagnostics unit.

The license enables Genoptix to use the biomarker analysis technology for cancer diagnostics in the US.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.